5 résultats
Stratification of pleural mesothelioma patients for combined immunotherapy based on sarcomatoid component and tumour microenvironment markers in the IFCT-MAPS2 study
Auteurs / Authors
G. Tosato, Y. Blum, J-B. Assié, R. Sequeiros
, A. Langlais
,
M. Arnould
, F. Damiola
, E. Amour, C. Meiller
, M-C. Jaurand
,A. de Reynies
, V. Westeel
, J. Mazieres
, L. Greillier
, F. Morin
,S. Lantuejoul
, A. Scherpereel, G. Zalcman, D. Jean
Journal / Conference
ELCC
Année / Year
2025
PMID / session
Etude IFCT
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Auteurs / Authors
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G, on behalf of the French Cooperative Thoracic Intergroup
Journal / Conference
The Lancet Oncology
Année / Year
2019
PMID / session
Etude IFCT
Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)
Auteurs / Authors
Zalcman G, Mazieres J, Greillier L, Brosseau S, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Planchard D, Ligeza-Poisson C, Amour A, Morin F, Moro-Sibilot D, Scherpereel A.
Journal / Conference
ESMO
Année / Year
2019
PMID / session
Etude IFCT
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
Auteurs / Authors
Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, Pascal Dô, Olivier Bylicki, Isabelle Monnet, Romain Corre, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez, Olivier Molinier, Luc Thiberville, Thierry Urban, Catherine Ligeza-poisson, David Planchard, Elodie Amour, Franck Morin, Denis Moro-Sibilot, Gerard Zalcman
Journal / Conference
ASCO
Année / Year
2017
PMID / session
Etude IFCT
Second or 3rd line Nivolumab (Nivo) versus Nivo plus Ipilimumab (Ipi) in Malignant Pleural Mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.
Auteurs / Authors
Zalcman G, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Thiberville L, Urban T, Planchard D, Ligeza-Poisson C, Amour A, Morin F, Moro-Sibilot D, Scherpereel A
Journal / Conference
ESMO
Année / Year
2017
PMID / session
Etude IFCT